文献速递免疫规划卫生政策与健康促进

研发和实施登革热疫苗的经济前景:系统综述证据

The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review.
PubMed 文献 · Vaccine · 2016-10-31

该系统综述检索多个数据库1970年1月至2016年2月发表的文献,纳入11项经济学研究,质量评估显示证据质量满意。基于模型的经济学证据表明,与病媒预防策略相比,登革热疫苗在价格适中时具有经济优势,但疫苗效力和每剂成本仍存在不确定性。

要点

  • 纳入11项经济学研究,证据质量经三种清单评估为满意水平。
  • 模型证据表明登革热疫苗较病媒预防策略具有经济优势。
  • 疫苗效力和每剂成本的不确定性仍存,结论基于模型。

核心结论

  • 综述的经济学证据提示,登革热疫苗在价格适中时具有经济优势,但疫苗效力仍存在不确定性,未来研究需用实际成本和效力数据确认模型发现。

研究设计与样本

  • 系统综述检索PubMed/Medline、Embase、Web of Science、Global Health、NHS经济评价数据库(NHS EED)和拉丁美洲与加勒比健康科学文献库(LILACS),检索限1970年1月至2016年2月发表的论文。
  • 纳入11项相关研究,使用三种公认清单进行质量评估。

主要发现

  • 共识别11项相关研究,经济学证据质量满意,证据通过模型方法得出。
  • 模型证据表明,与病媒预防策略相比,登革热疫苗具有经济优势,但疫苗效力和每剂成本存在不确定性。
  • 基于清单的质量评估显示类似结果,总体质量满意,但综述纳入的研究中未考虑若干相关方法学问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 疫苗效力和每剂成本仍存在不确定性。
  • 综述纳入的研究中未考虑若干相关方法学问题。
  • 未来研究需用实际成本和效力数据确认经济模型的发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dengue fever is one of the most rapidly advancing viral vector-borne diseases worldwide and vaccine candidates are in the final stages of clinical trials, representing a decisive opportunity to control the disease. To decide whether and where to support the introduction of new vaccines it is crucial to assess costs imposed by the disease and cost-effectiveness of vaccine programmes. OBJECTIVE: To identify economic evidence about dengue fever immunization, by systematic review, to assist future policy decisions and investment. METHODS: The electronic search stage was conducted on PubMed/Medline, Embase, Web of Science, Global Health, NHS Economic Evaluation Database (NHS EED) and Latin American and Caribbean Health Sciences Literature (LILACS) databases. Searches were restricted to papers published between January 1970 and February 2016. Selected papers were quality assessed using three recognized checklists. RESULTS: Eleven relevant studies were identified and there is economic evidence of a satisfactory quality level, derived through modelling approaches, to conclude that dengue fever vaccines will be economically advantageous when compared to vector preventive strategies, despite uncertainties surrounding vaccine efficacy and costs per vaccine dose. Quality assessment based on checklists showed similar findings and although overall quality was considered satisfactory, there were relevant methodological issues not considered among studies reviewed. CONCLUSION: Several uncertainties still remain about effectiveness of dengue fever vaccines; however, the reviewed economic evidence suggests that, when available, the vaccine can be economically advantageous at moderate prices. Future research needs to confirm findings from the economic models by using actual costs and effectiveness data.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Endo IC, Ziegelmann PK, Patel A, et al. The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review. Vaccine. 2016. PMID: 27810313. doi:10.1016/j.vaccine.2016.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。